News Details

Ecuador's health regulatory authority has issued one of the most comprehensive overhauls of its medical device framework in nearly a decade, signing into law a new technical standard that will govern how medical devices are registered, monitored and controlled across the country.

The resolution, signed on 28 April 2026 by ARCSA's Executive Director Dr. Daniel Antonio Sánchez Procel, replaces rules that had been in place since 2016 and introduces a significantly modernised approach to health product regulation. One that, for the first time, explicitly addresses technologies such as artificial intelligence and machine learning-enabled medical devices.

A New Era for Medical Device Oversight

At its core, the regulation establishes the conditions under which any natural person or company, whether Ecuadorian or foreign, public or private, must obtain a sanitary registry before they can manufacture, import, distribute or sell a medical device within Ecuador. No product may legally reach patients or healthcare providers without first clearing this process.

The scope of what qualifies as a medical device under the new rules is notably broad. Beyond the obvious, surgical instruments, implants, diagnostic equipment and in-vitro test kits, the regulation now formally encompasses dental products, biochemical reagents, and software systems that perform medical functions independently of any physical hardware. An AI-powered diagnostic tool, for instance, would fall squarely within its reach.

Risk-Based Approach at the Heart of the Framework

Central to the new system is a four-tier risk classification that will determine how stringent the requirements are for any given product. Devices classified as low risk face lighter documentation burdens, while those at the highest risk level, such as implantable devices that remain inside the body for more than thirty days, must meet significantly more demanding standards, including biocompatibility studies, clinical trials and evidence of functional performance under real-world conditions..

A Fast Track for Internationally Approved Products

One of the more consequential changes introduced by the resolution is a simplified registration pathway for medical devices that have already been approved by what the regulation terms "high surveillance agencies", bodies such as the United States Food and Drug Administration or the European Medicines Agency, provided those agencies are also members of the IMDRF.

Under this streamlined route, manufacturers will be able to obtain Ecuadorian sanitary registration in as little as thirty working days, compared to a considerably longer process under the general pathway. Officials argue the measure will help ensure that internationally proven, high-quality products reach Ecuadorian patients more quickly, without compromising safety oversight.

Keeping Pace with Technology

Perhaps the most forward-looking aspect of the new regulation is its explicit recognition of emerging medical technologies. For the first time, Ecuador's regulatory framework formally defines and addresses software as a medical device, machine learning-enabled medical devices, and AI-driven diagnostic tools, categories that had not existed when the previous rules were drawn up in 2016.

The inclusion signals that Ecuadorian authorities are seeking to ensure their oversight structures do not fall behind the pace of technological change, a challenge facing health regulators across Latin America and beyond.

Post-Market Surveillance Tightened

The regulation also substantially strengthens what happens after a device has been approved and reaches the market. ARCSA will conduct two levels of post-registry control: a first tier involving visual inspections of labelling and storage conditions, and a more intensive second tier in which physical samples are taken and submitted to laboratory analysis to verify that products continue to meet the standards under which they were originally approved.

Manufacturers, distributors and healthcare professionals alike will be legally obligated to report any adverse events linked to medical devices through Ecuador's National Technovigilance System. Failure to comply will be subject to sanctions under the country's Organic Health Law.

When Will It Take Effect?

Despite being signed at the end of April 2026, the regulation will not enter into force immediately. In accordance with Andean Community norms, which require a minimum period between publication and implementation to allow businesses and institutions time to adapt, the new rules will become binding nine months after signing, placing the effective date around January 2027.

ARCSA has the same nine-month window to produce the detailed instructional guides that will accompany the regulation, providing practical guidance on how its various requirements should be applied in specific situations.

The resolution represents a significant step in Ecuador's broader push toward regulatory modernisation, a policy priority formally declared by executive decree in 2024. For the medical device industry, both domestic manufacturers and international companies seeking access to the Ecuadorian market, it marks the beginning of a period of adaptation to a framework that is, by any measure, considerably more demanding and more technically sophisticated than the one it replaces.